NCT05189106View on ClinicalTrials.gov

Neurodegenerative Alzheimer's Disease and Amyotrophic Lateral Sclerosis (NADALS) Basket Trial

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

December 5, 2022

Primary Completion Date

February 27, 2025

Study Completion Date

June 1, 2025

Conditions
Amyotrophic Lateral SclerosisAlzheimer DiseaseMild Cognitive Impairment
Interventions
DRUG

Baricitinib

Each participant will be treated with open-label baricitinib for 24 weeks. Participants will receive 2 mg baricitinib by mouth daily for the first 8 weeks and 4 mg baricitinib by mouth daily for the remaining 16 weeks.

Trial Locations (2)

02129

Massachusetts General Hospital - ALS Site, Boston

Massachusetts General Hospital - AD Site, Charlestown

All Listed Sponsors
lead

Massachusetts General Hospital

OTHER